Physician profile
Peter S Park
NPI 1154937241
$2,193.14
in general payments reported to CMS, 2019-2025
22 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $284 · 2022: $235 · 2023: $704 · 2024: $600 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $653.69 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $605.31 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $185.82 | 2021-2025 | |
| Novo Nordisk INC | $170.36 | 2021-2025 | Rybelsus, Wegovy, Ozempic |
| Daiichi Sankyo INC. | $87.36 | 2024-2025 | Injectafer |
| Sanofi Pasteur INC. | $64.45 | 2021-2024 | |
| Lilly USA, LLC | $62.71 | 2022-2024 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $48.28 | 2024 | |
| Sunovion Pharmaceuticals INC. | $45.48 | 2021 | |
| Lundbeck LLC | $34.08 | 2022-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $29.20 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $23.81 | 2023 | Austedo |
| Harmony Biosciences LLC | $21.65 | 2022 | |
| Integra Lifesciences Corporation | $21.02 | 2023 | Duraseal Exact Spinal Sealant System, Codman Hakim, Codman Certas |
| Viatris Specialty LLC | $20.70 | 2025 | Yupelri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $19.69 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.39 | 2025 | Trintellix |
| Axsome Therapeutics, INC. | $19.13 | 2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $17.90 | 2021 | |
| Merck Sharp & Dohme LLC | $17.63 | 2021 | |
| Dexcom, INC. | $16.20 | 2021 | |
| Cardiovascular Systems INC. | $9.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.